Ehlers-Danlos Syndrome (EDS) and MCS: What Connects Them

EDS is a genetic connective-tissue disorder. Chemicals do not cause it and cannot change your collagen. But a large share of people with hypermobile EDS also develop Mast Cell Activation Syndrome — and MCAS is one of the clearest, most testable drivers of chemical sensitivity on this site.

No, chemicals do not cause EDS — it is a genetic disorder of collagen production, present from birth or conception, full stop. What connects EDS to chemical sensitivity is a third condition, Mast Cell Activation Syndrome (MCAS), which shows up far more often in people with hypermobile EDS than in the general population. When MCAS is present, ordinary chemical exposures — fragrance, VOCs, exhaust — can trigger an outsized mast-cell reaction. That reaction is the trigger, not the cause. Your genetics build the underlying vulnerability; MCAS is the mechanism that turns chemical exposure into a symptom.

What Is Ehlers-Danlos Syndrome?

Ehlers-Danlos Syndrome is a group of hereditary connective-tissue disorders caused by mutations in genes that instruct the body how to build and process collagen — the structural protein that gives skin, joints, and blood vessels their strength and elasticity.

The hypermobile subtype (hEDS), the one most relevant to this page, produces the hallmark stretchy skin, joint hypermobility, and joint instability that most people associate with the condition.

You are either born with the inherited mutation or it occurs spontaneously (de novo) at conception. There is no version of EDS caused by chemical exposure, VOCs, petroleum derivatives, or any other environmental toxin — that distinction matters, because it is easy to see chemicals discussed alongside EDS and assume a causal link that does not exist.

If Chemicals Don’t Cause EDS, Why Are They Discussed Together?

Because a large share of people with hypermobile EDS also have Mast Cell Activation Syndrome — and MCAS is a well-documented driver of reactivity to everyday chemicals.

Mast cells are a normal, essential part of the immune system. In MCAS, they become hyperactive and release inflammatory mediators — histamine among them — in response to triggers that would not bother a typical immune system, including VOCs from paint and new carpet, synthetic fragrance, and exhaust or smoke.

For someone with both EDS and MCAS, a chemical exposure that a bystander doesn’t register at all can produce flushing, fatigue, brain fog, joint pain flares, or in severe cases an anaphylactoid reaction. The genetics build the connective-tissue vulnerability — the cause. MCAS is the mechanism that turns an everyday chemical into a trigger.

Cause vs. Trigger — the Distinction That Matters

Genetics build the underlying condition. Chemical exposure does not cause EDS — it can inflame the mast-cell system that frequently travels with it. Confusing the two leads to two different mistakes: assuming EDS itself is an environmental illness (it isn’t), or dismissing a real chemical-triggered reaction as unrelated to a genetic diagnosis (it can be very related, through MCAS).

How Often Do EDS and MCAS Occur Together?

The honest answer is: the association is real in several large studies, but it is not settled science, and a recent multicenter review found no clear link at all. Both findings are worth knowing.

The Case for a Strong Link

  • A 2020 review in Clinical Reviews in Allergy & Immunology — the most-cited paper on this overlap — proposed a bidirectional interaction between fibroblasts and mast cells in connective tissue as a candidate shared mechanism between hEDS, MCAS, and POTS.[76]
  • An analysis of the National Inpatient Sample found that among 37,665 hospitalized patients carrying either diagnosis, 29.8% of those with MCAS also had an hEDS diagnosis — a rate far above what chance co-occurrence would predict, though concurrent diagnosis also rose sharply as clinical awareness of the overlap grew.[77]
  • A 2022 retrospective chart review reported statistically significant increases in both MCAS (odds ratio 5.26) and chronic spontaneous urticaria (odds ratio 6.07) among hEDS patients compared to expected general-population rates.

The Case Against It

A 2026 multicenter retrospective review by Mayo Clinic — covering all Mayo sites, 2017 to 2025 — found no clear association between MCAS and either hEDS or POTS, directly contradicting the earlier inpatient-sample findings.[78] The review's stated reason for existing was that a prior systematic review had already flagged the lack of standardized, validated diagnostic criteria across all three conditions as the likely source of the inconsistent findings.

Why the disagreement? Most likely, inconsistent diagnostic criteria. MCAS in particular has no single agreed diagnostic standard across the studies above — some rely on ICD hospital-billing codes, others on chart-reviewed clinical criteria, and those methods do not always find the same patients. Until the field standardizes how MCAS is diagnosed, studies using different criteria will keep producing different overlap numbers. That is a real limitation in the evidence, not something this page can resolve by picking the study it likes best.

What does this mean if you have EDS and react to chemicals?

Take it seriously and act on what you can see. An uncertain research picture does not make your reactions less real — if fragrance or off-gassing reliably triggers flares, that pattern is worth working with now.

An uncertain research picture doesn’t make your reactions any less real. If you have EDS and notice that fragrance, new-carpet off-gassing, or exhaust reliably triggers flushing, fatigue, brain fog, or joint pain flares, that pattern is worth investigating regardless of which way the population-level statistics eventually settle — the studies above disagree about how common the overlap is, not about whether MCAS itself can do this to a chemically exposed person.

The practical path is the same one this site walks through for any suspected MCAS-driven sensitivity:

  • MCS testing — the mast cell markers (tryptase, plasma histamine) that can support or rule against a MCAS contribution.
  • Mast cell stabilization pathway — prescription and natural stabilizers, antihistamine combinations, and the low-histamine diet approach.
  • Triggers and avoidance — reducing the VOC, fragrance, and exhaust exposures most likely to provoke a reaction.

Important Medical Notice

EDS, MCAS, and MCS should each be evaluated and diagnosed by qualified healthcare providers familiar with connective-tissue and mast-cell disorders. This page is educational and does not replace individualized medical care or diagnosis.

References & Citations

The EDS genetics and definitional material on this page draws on established clinical understanding of hereditary connective-tissue disorders. The association claims are individually cited to the Research Library: [76] Kohn & Chang, Clin Rev Allergy Immunol 2020; [77] National Inpatient Sample analysis, 2021; [78] Mayo Clinic multicenter review, JACI 2026. For the full MCAS mechanism evidence and complete citations, see the Research Library →

← Back to MCSDisability.com